Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. - Wikidata - wikimedia - TriplyDB

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

http://www.wikidata.org/entity/Q33832088

about

Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.Secondary B cell receptor diversification is necessary for T cell mediated neuro-inflammation during experimental autoimmune encephalomyelitis.Preventing autoimmunity protects against the development of hypertension and renal injury.Understanding autoimmunity in the eye: from animal models to novel therapies.Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.Effects of B Cell Depletion on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques.Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity.Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barré syndrome as well as their animal models.Is rituximab effective in childhood nephrotic syndrome? Yes and no.B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus.The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models.Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.Repetitive hypoxic preconditioning induces an immunosuppressed B cell phenotype during endogenous protection from stroke.B-cell targeting agents in the treatment of multiple sclerosis.Amelioration of EAE by a cryptic epitope of myelin oligodendrocyte glycoprotein.Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.Imaging B cells in a mouse model of multiple sclerosis using 64Cu-Rituximab-PET.Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review.Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis.Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain.Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis

P2860

Q28067334-C1AA1260-C501-4D67-BC5D-D27D90FDB6C4 Q30388433-A1E86349-A3BD-49FB-9E22-0AE3A08A5C2D Q33849373-3B6090BB-E90F-4A1F-8A61-9D5B1FC44A78 Q34413247-BE7964A4-7FD5-4570-B9CC-8C46EF514AD7 Q34613311-4336DDF4-FFB5-4624-AE51-FC86B97A2C58 Q34684427-0FBE906E-C6E5-4618-BC61-4FF5D185A536 Q35159241-EBB94ED4-16CF-4072-83A3-847D913A69B6 Q36069594-D9D9AC0F-1A31-4DAF-98A9-A4C7B901A795 Q36506677-709B4D43-EE61-493E-8378-96E076A288BD Q36803471-575E894F-12B7-4A07-BE8B-609B9D920DD9 Q36888486-C26E89CB-E887-41EA-B206-D244D931907F Q37995305-90C5D4F8-A968-430B-9ED2-2AE18411606F Q38105052-B329E79B-2BF1-4204-AB3E-71AF0FAA8108 Q38118894-1F80879C-8A3C-48D8-A7C0-C1BE54FAE15A Q38159695-6288E553-AD50-4921-84F8-149BD56282A4 Q38186206-F60E9316-D564-491F-BE8A-7A06A35AE2DA Q38256670-D070EF0D-72DC-41B8-BCAF-16706CAA42FB Q38653397-5992D928-743D-4A77-974E-ED170DC59732 Q38679589-5C64166D-350F-4D5A-B320-684405C9CD80 Q38932141-16D6DBB4-0202-4AC1-B711-A6EBE8254381 Q39258820-EFEA2C35-13F5-4E0D-8251-8CC0D570209D Q39431517-BF41D6CE-8EAF-49F3-8A5E-E11F6BEF9C67 Q39594953-183017B5-B293-4725-8A41-37E5BA4366C9 Q40110864-F5FE6571-1F97-43CC-98D1-A694F622BC47 Q40484475-E95ECDED-C8D9-4F01-943C-9D80E1456AF7 Q41660408-67800321-EC97-434D-9735-492C96597EF1 Q41879482-0541B435-3FAB-4F7F-9679-32D6F8D462BE Q43026083-79C9EA9B-5309-4B73-B6F0-B53BAFD58FE9 Q58758199-60349664-DCB9-43A8-BBD0-56D0514221B4 Q58796101-94610D3E-0A48-436C-9239-581ED3762FF0

P2860

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

http://www.wikidata.org/entity/Q33832088

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Rituximab therapy reduces orga ...... autoimmune encephalomyelitis.

@ast

Rituximab therapy reduces orga ...... autoimmune encephalomyelitis.

@en

type

label

Rituximab therapy reduces orga ...... autoimmune encephalomyelitis.

@ast

Rituximab therapy reduces orga ...... autoimmune encephalomyelitis.

@en

prefLabel

Rituximab therapy reduces orga ...... autoimmune encephalomyelitis.

@ast

Rituximab therapy reduces orga ...... autoimmune encephalomyelitis.

@en

P1433

Q33832088-9D17193F-EFE1-4396-82DA-5B1FAE25AA6A

P1476

Q33832088-DE989029-EDCA-4BB4-A16E-1237963F10FF

P2093

Q33832088-3EFB6D2D-36FA-4838-9CDB-5FCB1EA59842

Q33832088-55BFF024-A3AF-40BE-80A8-2415604D95D6

Q33832088-62B457E1-CA54-4610-8B4C-1D4E0E025E1F

Q33832088-6B8580B0-F833-4AE7-94F5-D7DAE79DEA96

Q33832088-77352BC4-C6AF-46B0-A530-2032544DBADD

Q33832088-799DDE6F-23FB-4966-8EC7-FF2F82857E80

Q33832088-80B06BD8-55E8-4D78-B8FA-CF63F988264E

Q33832088-86B10AB4-4533-4643-BB7D-7A8FE2431E4B

Q33832088-8B419E48-56AC-41FF-8B5E-7507EEB0D356

Q33832088-95D5543C-5C8F-456B-B7D0-FCFE3706FCB5

P2860

Q33832088-17392764-5E75-439E-9DB5-3D6C5B33B60C

Q33832088-1DFB26B2-B0ED-456F-A1B0-BBF6719B050C

Q33832088-341A3E41-1909-4EB9-BEC4-83829677C79A

Q33832088-43AB1637-C7BC-4EA2-8BDD-1BD98598497E

Q33832088-45B2048E-7ED9-4D7E-AF00-1AF654496CE9

Q33832088-6D7F2655-48E5-488D-9C68-4D7ABFA746D5

Q33832088-720C67C6-0A43-4087-8B6B-7BA2324691EC

Q33832088-89AC51D9-08A2-44F8-A836-2F7E8ED0D16D

Q33832088-983260D2-FF3F-4549-9835-7EE7B6188EC5

Q33832088-BC545DFC-5D41-43CF-93F4-85C29B15F6B6

P304

Q33832088-E7DB6DEB-0FFF-4BBE-980D-F128AFFE4A5C

P31

Q33832088-459AC442-F3D0-4857-9357-D0937729A962

P356

Q33832088-827A00CE-986F-459B-9AF3-C65478A1D7FD

P407

Q33832088-C64C4F90-F46F-4010-ABF6-5A9032A636D2

P433

Q33832088-C0285E3A-8168-4EA6-976A-9DE9D3A6E594

P478

Q33832088-4F5C145C-E8D8-448A-872A-F44E3ECFF6F2

P50

Q33832088-1F39F02C-9A38-4034-8C12-34DDB5F597CC

Q33832088-9626B237-4B77-46C5-A817-01103A0CB4D9

P577

Q33832088-C7FD3D6C-0C7F-4558-A179-47D4281F32E7

P5875

Q33832088-5181C820-6CC1-4D0D-B410-36EFFA188C3E

P698

Q33832088-9CA8AFDD-8490-4A85-B78D-CB67FC597087

P921

Q33832088-403A1609-FB89-4133-9ED6-626AC339F975

P932

Q33832088-3273B48B-1D8F-4DC3-BC0B-25B11DA354C8

P356

JOURNAL.PONE.0017103

P1433

P1476

Rituximab therapy reduces orga ...... autoimmune encephalomyelitis.

@en

P2093

Amy Lovette-Racke

http://www.w3.org/2001/XMLSchema#string

Christopher T Harp

http://www.w3.org/2001/XMLSchema#string

Jeri-Anne Lyons

http://www.w3.org/2001/XMLSchema#string

Julie Do

http://www.w3.org/2001/XMLSchema#string

Li-Hong Ben

http://www.w3.org/2001/XMLSchema#string

Maria de Pilar Martin

http://www.w3.org/2001/XMLSchema#string

Mark Shlomchik

http://www.w3.org/2001/XMLSchema#string

Matthew Cummings

http://www.w3.org/2001/XMLSchema#string

Michael K Racke

http://www.w3.org/2001/XMLSchema#string

Nancy L Monson

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

B cells regulate autoimmunity by provision of IL-10.

Rituximab: ongoing and future clinical development.

Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.

Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.

Novel approaches and cutting edge immunotherapies in multiple sclerosis.

B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity

Potential role of humoral immunity in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

P304

e17103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0017103

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50228269

http://www.w3.org/2001/XMLSchema#string

P698

21359213

http://www.w3.org/2001/XMLSchema#string

P921

experimental autoimmune encephalomyelitis

P932

3040191

http://www.w3.org/2001/XMLSchema#string